Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5988937 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL2369806 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL7276173 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL3172850 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL3173441 | 1.00 | TBXAS1 (0.79) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL3530240 | 0.98 | TBXAS1 (0.76) | TBXAS1 | |
| SCHEMBL139976 | 0.98 | TBXAS1 (0.75) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL7276913 | 0.96 | TBXAS1 (0.72) | TBXAS1 | |
| Bromide SCHEMBL18941395 | 0.96 | TBXAS1 (0.72) | TBXAS1 | |
| SCHEMBL9253280 | 0.91 | TBXAS1 (0.71) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116718657-A | Preparation method of glucose biological sensing membrane and glucose biological sensor | 深圳木芯科技有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-116718657-A | Preparation method of glucose biological sensing membrane and glucose biological sensor | 深圳木芯科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20190169342-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169342-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. | 2019-06-06 | — | — | US | disclosed |
| EP-3130343-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-3130343-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2538947-B1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2538947-B1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20130189215-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130189215-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| EP-0230035-B1 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID CO (US) | 1994-10-12 | — | — | EP | disclosed |
| US-5081131-A | Omega-((hetero)alkyl)benz(cd)-indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0230035-A2 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4619941-A | N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane synthetase inhibitors and antihypertensive agents | AMERICAN CYANAMID COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
| US-4576957-A | HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4568687-A | THROMBOXANE SYNTHETASE TNZYME INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-02-04 | — | — | US | disclosed |
| US-4555519-A | Thromboxane synthetase enzyme inhibiting N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]pyridinecarboxamides | AMERICAN CYANAMID COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
| US-4489089-A | INHIBITION OF THE ENZYME THROMBOXANE SYNTHETASE | AMERICAN CYANAMID COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0127727-A2 | Substituted N-(omega-(1H-imidazol-1-yl)alkyl)) amides | AMERICAN CYANAMID COMPANY (US) | 1984-12-12 | — | — | EP | disclosed |
| US-4320134-A | HYPOTENSIVE, ANTIASTHMATIC AND ANTIINFLAMMATORY AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189215-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, ITCH | TBXAS1 2184/4885 |
| US-20190169342-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, ITCH | TBXAS1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.